Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...
Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development. The deal – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback